WordNet

cessation from or slowing of activity during the winter; especially slowing of metabolism in some animals
the torpid or resting state in which some animals pass the winter
the act of retiring into inactivity; "he emerged from his hibernation to make his first appearance in several years"
of or relating to the myocardium

PrepTutorEJDIC

冬眠

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 気絶心筋または冬眠心筋の病態生理pathophysiology of stunned or hibernating myocardium [show details]
…percent of myocardial segments that were hypokinetic had normal myocardium when examined histologically compared to only 7 percent of akinetic or dyskinetic segments . Myocardial hibernation may be acute …
2. 冠動脈疾患の核イメージングによる心筋生存能の評価assessment of myocardial viability by nuclear imaging in coronary heart disease [show details]
…infarcted myocardial tissue. It is now understood that, among patients with ischemic cardiomyopathy, LV systolic dysfunction can result from myocardial necrosis and remodeling, myocardial hibernation, or repetitive …
3. Approach to evaluation of the right ventricle in adultsapproach to evaluation of the right ventricle in adults [show details]
…ischemic heart disease commonly have RV as well as LV dysfunction . In the clinical syndrome of RV myocardial infarction (MI), RV ischemia or infarction causes RV dysfunction, which is commonly but not always …
4. 気絶心筋または冬眠心筋の臨床的症候群clinical syndromes of stunned or hibernating myocardium [show details]
…recovery; most of the improvement occurred by day 14, consistent with the concept of myocardial stunning. Myocardial hibernation in patients with MI can occur both in the area of infarction and in a region of …
5. 心筋虚血状態：臨床的意義myocardial ischemic conditioning clinical implications [show details]
…the long-term development of coronary collateral vessels and myocardial hibernation and stunning. The potential clinical use of myocardial ischemic conditioning to improve outcomes in patients with coronary …

English Journal

Impact of imaging protocol on left ventricular ejection fraction using gated-SPECT myocardial perfusion imaging.

Marcassa C1, Giubbini R2, Acampa W3, Cittanti C4, Djepaxhija O5, Gimelli A6, Kokomani A5, Medolago G7, Milan E8, Sciagrà R5.
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.J Nucl Cardiol.2016 Apr 6. [Epub ahead of print]
BACKGROUND: There are limited data on the impact of the imaging protocol (single-day stress-rest, SD, vs. dual-day, DD) on the change in left ventricular (LV) ejection fraction (EF) (post-stress-rest) in relation to ischemia and on outcome.METHODS: Using propensity score matching procedure, 490 of 1
PMID 27052809

An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy.

Midaglia L1, Juega Mariño JM2, Sastre-Garriga J3, Rovira A4, Vidal-Jordana A3, López-Pérez MA2, Marzo-Sola ME2, Librada Escribano F5, Montalban X3.
Multiple sclerosis (Houndmills, Basingstoke, England).Mult Scler.2016 Mar 18. pii: 1352458516638557. [Epub ahead of print]
BACKGROUND: Clinically isolated syndromes affecting the brainstem may present with rare manifestations such as neurogenic pulmonary oedema (NPO).OBJECTIVES: We present the case of a 23 year-old man with NPO caused by Tako-Tsubo cardiomyopathy (TTC) as a first manifestation of multiple sclerosis (MS)
PMID 26993120

ORM-3819 promotes cardiac contractility through Ca(2+) sensitization in combination with selective PDE III inhibition, a novel approach to inotropy.

Nagy L1, Pollesello P2, Haikala H2, Végh Á3, Sorsa T2, Levijoki J2, Szilágyi S1, Édes I1, Tóth A1, Papp Z4, Papp JG5.
European journal of pharmacology.Eur J Pharmacol.2016 Mar 15;775:120-9. doi: 10.1016/j.ejphar.2016.02.028. Epub 2016 Feb 9.
This study is the first pharmacological characterization of the novel chemical entity, ORM-3819 (L-6-{4-[N'-(4-Hydroxi-3-methoxy-2-nitro-benzylidene)-hydrazino]-phenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one), focusing primarily on its cardiotonic effects. ORM-3819 binding to cardiac troponin C (cT
PMID 26872993